XTX Topco Ltd Buys New Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

XTX Topco Ltd purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,086 shares of the company’s stock, valued at approximately $74,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter worth $265,000. State Street Corp boosted its holdings in Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares during the last quarter. Nwam LLC bought a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $53,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after buying an additional 53,809 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $89,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $4.99 on Friday. The business’s fifty day moving average price is $8.12 and its 200-day moving average price is $5.09. Corvus Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $10.00. The stock has a market capitalization of $320.64 million, a PE ratio of -5.37 and a beta of 1.05.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CRVS shares. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Oppenheimer boosted their price target on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $12.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.